Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Heidi StorgaardLise L GluudCathy BennettMagnus F GrøndahlMikkel B ChristensenFilip K KnopTina Vilsbøll

Published in: PloS one (2016)

This review includes a large number of patients with type 2 diabetes and found that SGLT2-i reduces HbA1c with a notable increased risk in non-serious adverse events. The analyses may overestimate the intervention benefit due bias.

Keyphrases

randomized controlled trial